Filter Results:
(925)
Show Results For
- All HBS Web
(1,280)
- People (5)
- News (171)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Show Results For
- All HBS Web
(1,280)
- People (5)
- News (171)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Sort by
- Article
Pharmaceutical Marketing Practices in the Third World
By: N. Craig Smith and John A. Quelch
Smith, N. Craig, and John A. Quelch. "Pharmaceutical Marketing Practices in the Third World." Special Issue on Quality of Life. Journal of Business Research 23, no. 1 (August 1991): 113–126.
- February 2014
- Teaching Note
Mylan Lab's Proposed Merger with King Pharmaceuticals
By: Lucy White
Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders,... View Details
- June 2002 (Revised November 2005)
- Case
Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa
By: Debora L. Spar
In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a... View Details
Keywords: Patents; Health Pandemics; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Africa
Spar, Debora L., and Nick Bartlett. "Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa." Harvard Business School Case 702-049, June 2002. (Revised November 2005.)
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details
Keywords: Public Sector; Science-Based Business; Research and Development; Sovereign Finance; Pharmaceutical Industry
Henderson, Rebecca, and Ian Cockburn. "Publicly Funded Science and the Productivity of the Pharmaceutical Industry." In Innovation Policy and the Economy, Volume 1, edited by Adam B. Jaffe, Josh Lerner, and Scott Stern, 1–34. MIT Press, 2001.
- 2019
- Article
Pay-for-Monopoly?: An Assessment of Reverse Payment Deals by Pharmaceutical Companies
By: Sana Rafiq and Max Bazerman
Abstract
Over the past eighteen years, pharmaceutical firms have developed a blueprint to impede competition in order
to maintain their monopoly profits. This scheme, termed pay-for-delay, involves direct or indirect payment of
money from a branded-drug manufacturer... View Details
Rafiq, Sana, and Max Bazerman. "Pay-for-Monopoly? An Assessment of Reverse Payment Deals by Pharmaceutical Companies." Journal of Behavioral Economics for Policy 3, no. 1 (2019): 37–43.
- December 2005
- Article
Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry
This paper argues that the pharmaceutical industry represents an exciting opportunity to carry out academic research. The nature of the industry allows researchers to answer new questions, develop new methodologies for answering these questions as well as to apply... View Details
Manchanda, Puneet, Dick R. Wittink, Andrew Ching, Paris Cleanthous, Min Ding, Xiaojing J. Dong, Peter S. H. Leeflang, Sanjog Misra, Natalie Mizik, Sridhar Narayanan, Thomas J. Steenburgh, Jaap E. Wieringa, Marta Wosinska, and Ying Xie. "Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry." Marketing Letters 16, nos. 3/4 (December 2005): 293 – 308.
- July 1998 (Revised October 1998)
- Case
Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry
By: Carin-Isabel Knoop and Anthony St. George
Jan Eriksson is the country manager of the Indonesian joint venture of Basel-based Novartis (Novartis Indonesia), the world's largest pharmaceutical company, formed by the 1996 merger between Sandoz and Ciba-Geigy. The case describes the actions he has taken since... View Details
Keywords: Joint Ventures; Mergers and Acquisitions; Crisis Management; Management Teams; Financial Crisis; Pharmaceutical Industry; Indonesia
Knoop, Carin-Isabel, and Anthony St. George. "Jan Eriksson at Novartis Indonesia: Turmoil in the Indonesian Pharmaceutical Industry." Harvard Business School Case 899-040, July 1998. (Revised October 1998.)
- May 1998
- Teaching Note
Merck-Medco: Vertical Integration in the Pharmaceutical Industry TN
By: V. Kasturi Rangan and Marie Bell
Teaching Note for (9-598-091). View Details
Keywords: Pharmaceutical Industry
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Pharmaceutical Industry; Pharmaceutical Industry; San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- 2009
- Article
Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era
By: Arthur A. Daemmrich
This article presents a case study of the rise of Pfizer as a leading pharmaceutical company, with a focus on changing relationships between manufacturing technology and R&D between the mid-1940s and the mid-1960s. Pfizer first moved into pharmaceuticals through... View Details
Keywords: Research and Development; Production; Technology; Transformation; Relationships; Success; Organizations; Programs; Chemicals; Alignment; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era." History and Technology 23, no. 3 (2009): 237–256.
- November 1983
- Teaching Note
CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning, Teaching Note
By: Robert D. Buzzell
- January 2009 (Revised February 2014)
- Case
Mylan Lab's Proposed Merger with King Pharmaceutical (Abridged)
By: Lucy White
Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders,... View Details
Keywords: Mergers and Acquisitions; Voting; Ethics; Stock Shares; Investment; Lawsuits and Litigation; Ownership Stake
White, Lucy. "Mylan Lab's Proposed Merger with King Pharmaceutical (Abridged)." Harvard Business School Case 209-097, January 2009. (Revised February 2014.)
- fall 2007
- Article
Pharmaceutical Regulation in the United States and Europe
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Pharmaceutical Regulation in the United States and Europe." Focus on Law Studies 23, no. 1 (fall 2007): 8–11.
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Geographic Location; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Demand and Consumers; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- 2009
- Working Paper
Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
By: Arthur Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Disorders; Health Testing and Trials; Power and Influence; Competitive Strategy; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur. "Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location." Harvard Business School Working Paper, No. 09-118, April 2009.
- 8 Mar 2012
- Other Presentation
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health View Details
Porter, Michael E. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Creating Shared Value in Global Health, FSG, New York City, NY, United States , March 8, 2012.
- September 2017
- Teaching Note
Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry
By: Steven Rogers and Alyssa Haywoode
Teaching Note for HBS No. 318-005. View Details
- June 1989 (Revised July 1990)
- Background Note
Note on Pharmaceutical Marketing Practices in the Third World
Smith, N. Craig, and John A. Quelch. "Note on Pharmaceutical Marketing Practices in the Third World." Harvard Business School Background Note 589-039, June 1989. (Revised July 1990.)
- August 1994 (Revised March 1995)
- Supplement
Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)
Supplements the (A) case. View Details
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)." Harvard Business School Supplement 395-035, August 1994. (Revised March 1995.)
- December 1991
- Teaching Note
Eli Lilly and Co.: European Pharmaceutical Operations, Teaching Note
By: Francis Aguilar